Marı́a del Mar Masiá

Hospital General Universitario de Elche

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Victoria Ortiz de la Tabla

Universitat de Miguel Hernández d'Elx

Félix Gutiérrez

Hospital General Universitario de Elche

Félix Gutiérrez Rodero

Hospital General Universitario de Elche

Daniel Podzamczer

Bellvitge University Hospital

M H St Clair

Research Triangle Park Foundation

Feifan Zhang

Tibet University

W. Keith Henry

University College London

Kenneth Sutton

Triangle

Kimberly Y. Smith

ViiV Healthcare (United Kingdom)

Clara Escolano

Hospital General Universitario de Alicante Doctor Balmis

Cooperative Institutions

Hospital General Universitario de Elche

Hospital Marina Baixa

Universitat de Miguel Hernández d'Elx

Instituto de Salud Carlos III

Centro de Investigación Biomédica en Red

Janssen (Belgium)

Research Triangle Park Foundation

GlaxoSmithKline (United States)

Triangle

ViiV Healthcare (Spain)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Legionnaires' Disease in Patients Infected with Human Immunodeficiency Virus

Clinical Infectious Diseases (1995)

Félix Gutiérrez Rodero Victoria Ortiz de la Tabla Carlos de Ayala Martínez Marı́a del Mar Masiá E. Chiner

Journal Article Legionnaires' Disease in Patients Infected with Human Immunodeficiency Virus Get access Félix Gutiérrez Rodero, Félix Gutiérrez Rodero Servicios de Medicina Interna, Microbiología y Neumología, Hospital del SVS de Villajoyosa, Villajoyosa, Alicante, Spain Reprints or correspondence: Dr. Félix Gutiérrez Rodero, Servicio de Medicina Interna, Hospital del SVS de Villajoyosa, 03570 Villajoyosa, Alicante, Spain. Search for other works by this author on: Oxford Academic PubMed Google Scholar Victoria Ortiz de la Tabla, Victoria Ortiz de la Tabla Servicios de Medicina Interna, Microbiología y Neumología, Hospital del SVS de Villajoyosa, Villajoyosa, Alicante, Spain Search for other works by this author on: Oxford Academic PubMed Google Scholar Carmen Martínez, Carmen Martínez Servicios de Medicina Interna, Microbiología y Neumología, Hospital del SVS de Villajoyosa, Villajoyosa, Alicante, Spain Search for other works by this author on: Oxford Academic PubMed Google Scholar María del Mar Masiá, María del Mar Masiá Servicios de Medicina Interna, Microbiología y Neumología, Hospital del SVS de Villajoyosa, Villajoyosa, Alicante, Spain Search for other works by this author on: Oxford Academic PubMed Google Scholar Eusebio Chiner, Eusebio Chiner Servicios de Medicina Interna, Microbiología y Neumología, Hospital del SVS de Villajoyosa, Villajoyosa, Alicante, Spain Search for other works by this author on: Oxford Academic PubMed Google Scholar José Luis Calpe José Luis Calpe Servicios de Medicina Interna, Microbiología y Neumología, Hospital del SVS de Villajoyosa, Villajoyosa, Alicante, Spain Search for other works by this author on: Oxford Academic PubMed Google Scholar Clinical Infectious Diseases, Volume 21, Issue 3, September 1995, Pages 712–713, https://doi.org/10.1093/clinids/21.3.712 Published: 01 September 1995

10.1093/clinids/21.3.712

Cite

Citations (16)

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Open Forum Infectious Diseases (2021)

Graham Smith W. Keith Henry Daniel Podzamczer Marı́a del Mar Masiá Christopher Bettacchi

In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years.After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/Q4W groups) or switched from oral ART to Q8W or Q4W LA therapy (extension-switch groups). Endpoints assessed included proportion of participants with HIV-1 RNA <50 copies/mL (Snapshot algorithm) and adverse events (AEs).At week 256, 186 of 230 (81%) participants in randomized Q8W/Q4W groups and 41 of 44 (93%) participants in extension-switch groups had HIV-1 RNA <50 copies/mL. No protocol-defined virologic failures occurred after week 48. Injection wsite reactions infrequently resulted in discontinuation (4 [2%] and 1 [2%] participants in randomized Q8W/Q4W and extension-switch groups, respectively). Three participants in randomized Q8W/Q4W groups experienced drug-related serious AEs, including 1 fatal serious AE (Q4W group); none occurred in extension-switch groups. Of 25 participants with AEs leading to withdrawal, 20 were in the randomized Q4W group; no AE leading to withdrawal occurred in >1 participant.Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection.Clinical Trials Registration. NCT02120352.

Rilpivirine

Abacavir

Tolerability

Discontinuation

10.1093/ofid/ofab439

Cite

Citations (39)

Corynebacterium pseudodiphtheriticum: an easily missed respiratory pathogen in HIV-infected patients

Diagnostic Microbiology and Infectious Disease (1999)

Félix Gutiérrez Victoria Ortiz de la Tabla Carmen Martı́nez Marı́a del Mar Masiá Antonia Mora

AIDS-Related Opportunistic Infections

Opportunistic pathogen

10.1016/s0732-8893(98)00163-1

Cite

Citations (27)

Factores asociados a la resistencia a los inhibidores de la proteasa del virus de la inmunodeficiencia humana

Medicina Clínica (2002)

José Moltó Félix Gutiérrez Antonia Mora Marı́a del Mar Masiá Clara Escolano

Protease inhibitor (pharmacology)

HIV drug resistance

10.1016/s0025-7753(02)72512-8

Cite

Citations (10)

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study

Graham Smith W. Keith Henry Daniel Podzamczer Marı́a del Mar Masiá Christopher Bettacchi

Rilpivirine

Source

Cite

Citations (0)

Staphylococcal Toxic Shock Syndrome Associated with Human Immunodeficiency Virus Infection: Report of a Case with Bacteremia

Clinical Infectious Diseases (1996)

Félix Gutiérrez Rodero Victoria Ortiz de la Tabla Clara Janneth Santos Martínez Marı́a del Mar Masiá

Bacteremia

Toxic shock syndrome

10.1093/clinids/22.5.875

Cite

Citations (3)

Producción científica en España en enfermedades infecciosas (1991-2001): posición en el contexto de la Unión Europea

Enfermedades Infecciosas y Microbiología Clínica (2004)

José Manuel Ramos Marı́a del Mar Masiá Félix Gutiérrez

10.1016/s0213-005x(04)73026-8

Cite

Citations (12)

Endocarditis Caused by Stenotrophomonas maltophilia: Case Report and Review

Clinical Infectious Diseases (1996)

Félix Gutiérrez Rodero Marı́a del Mar Masiá Jorge Cortés Victoria Ortiz de la Tabla Vicente Mainar

Stenotrophomonas (Xanthomonas) maltophilia is a rare cause of endocarditis. The extensive resistance of this organism to several antibiotics leaves few options for antimicrobial therapy. In vitro synergism of the combination of trimethoprim-sulfamethoxazole (TMP-SMZ) and ticarcillin/clavulanic acid (TIC/CA) has been demonstrated. To our knowledge, we report the first case of ventriculoatrial cerebrospinal fluid shunt-associated endocarditis due to S. maltophilia. The patient was cured with combination therapy with TMP-SMZ and TIC/CA along with catheter removal. This is also the first report of S. maltophilia endocarditis successfully treated with this antibiotic combination. In a review of the medical literature, only 16 cases of S. maltophilia endocarditis were found. Most patients were intravenous drug users (43.8%) or had either prosthetic heart valves (50%) or an indwelling vascular catheter (18.8%). Although S. maltophilia is usually considered a nosocomial pathogen, about one-half of the cases were community-acquired. Twelve of sixteen patients had left-sided endocarditis. Therapy with a combination of two or more antibiotics was employed in most cases. Seven patients had been given TMP-SMZ therapy, but none had been treated with TIC/CA before. One-half of the patients required cardiac surgery. The overall mortality rate was 33%. Although the optimal antibiotic treatment for S. maltophilia endocarditis remains unknown, the case reported herein reinforces in vitro findings that the combination of TMP-SMZ and TIC/CA may be effective therapy.

Stenotrophomonas maltophilia

Ticarcillin

Infective Endocarditis

10.1093/clinids/23.6.1261

Cite

Citations (41)

Producción científica en España en enfermedades infecciosas (1991-2001): posición en el contexto de la Unión Europea

Enfermedades Infecciosas y Microbiología Clínica (2004)

José Manuel Ramos Marı́a del Mar Masiá Félix Gutiérrez

Web of science

Clinical Microbiology

10.1157/13056688

Cite

Citations (11)